Pancreatic islet transplantation for patients with diabetes mellitus has been hindered by the problem of donor shortage, as is the case for transplantation of other organs. Among several measures to overcome this problem, cell transplantation using xenogenic cell lines has been considered. For the treatment of diabetic patients, a murine pancreatic β-cell line MIN6 is a potential source of cell transplant. In order to restrict otherwise unlimited proliferation of transplanted MIN6 cells, cells are rendered to form spheroidal aggregates (SMIN6) on nonadherent culture dishes. SMIN6 stopped its growth around day 7 with a diameter of 220 ± 40 µm and kept its size almost constant at least until day 28. SMIN6 cells, however, had reduced responsiveness of insulin secretion to glucose concentration compared with MIN6 cells cultured in a monolayer. On the other hand, spheroid MIN6 cells formed in the presence of extracellular matrix gel (SMIN6E) possessed the capacity for glucose-dependent insulin secretion comparable with conventional MIN6 cells. SMIN6E encapsulated in agarose beads (SMIN6E-B) was also viable for at least 1 month in vitro with a constant diameter and favorable glucose responsiveness. The development of spheroid-type MIN6 may contribute to the future clinical application of MIN6 or other β-cell lines for treatment of diabetes mellitus.
INTRODUCTION
The pancreatic β-cell line MIN6, established from insulinoma developed in a transgenic mouse with SV40 T One of the major problems in organ transplantation antigen driven by insulin promoter, retains the ability has been the shortage of donors despite the extensive for glucose-dependent insulin secretion indistinguishcampaign to enroll more potential donors. To circumable from that of normal pancreatic β-cells (7). MIN6 vent this problem, several approaches are taken. These cells are a potential source of pancreatic β-cell transinclude transplantation of natural organs from living huplant if their antigenicity and proliferation are conman donors or xenogenic animals and artificial organs trolled. In the present study, we developed a spheroidmade of bioengineered cells, nonbiological material, or type MIN6 using a technique of tissue engineering and a combination of both. The choice of strategies depends succeeded in regulation of MIN6 cell proliferation. We on the target organs to be replaced. In the case of diabeconfirmed retention of glucose-dependent insulin secretes mellitus, where β-cells in the pancreatic islet are detion in the spheroid-type MIN6 even after encapsulation teriorated, use of the pancreatic islets from pigs has been in agarose microbeads, which protect transplants from pursued with limited success due to acute and chronic attack by the host immune system. rejection. On the other hand, immortalized β-cell lines are a potential source of insulin-producing cells, which MATERIALS AND METHODS are advantageous over xenogenic islets in that they can MIN6 Cell Culture be genetically modified to suppress attack from the host MIN6 is a pancreatic β-cell line established from inimmune system and in that they proliferate indefinitely sulinoma cells developed in a transgenic mouse with in vitro to serve grafts for millions of patients. One seri-SV40 T antigen driven by insulin promoter (7). MIN6 ous drawback is unlimited growth after transplantation. cells were cultured in Dulbecco's modified Eagle's me-Control of their proliferation is a prerequisite for clinical dium (DMEM) containing 25 mmol/L glucose, suppleapplication. mented with 12% heat-inactivated fetal bovine serum RESULTS (FBS) and penicillin, streptomycin, and amphotericin B
It has been reported that growth of an immortalized (GIBCO BRL) in a 100-mm 2 tissue culture dish. The cell line is strongly suppressed by three-dimensional culcells were incubated in humidified 5% CO 2 at 37°C. ture that induces spheroidal aggregates (6) . MIN6 cells Cells were harvested at 80% confluency after trypsinizacultured in nonadherent dishes spontaneously formed tion. MIN6 cells from passages 12 to 15 were used in spheroidal aggregates (SMIN6) by 1 day after inocuthis study. lation (Fig. 1 ). The diameter of spheroid at day 3 was 130 ± 40 µm (mean ± SD), which continued to increase Development of the Spheroid-Type MIN6 until day 7. From day 7 to day 28, however, the diameter of spheroid was constant at 220 ± 40 µm (Fig. 2) . The MIN6 cells cultured in a 100-mm 2 nonadherent plasnumber of living cells per spheroid estimated from actic dish adopted spheroidal morphology (SMIN6) by 1 tivity of a mitochondrial enzyme (WST assay) was apday after inoculation. Spheroidal MIN6 cells were also proximately 10 3 cells between day 7 and day 28 (data prepared in the presence of various concentrations (25%, not shown). This result implies that MIN6 cells may 6.25%, 1.56%, 0.39%, and 0.097%) of ECM gel (Sighave undergone cell cycle arrest or kept constant cell ma), which contains laminin, collagen type IV, heparin number by balanced proliferation and cell death. sulfate proteoglycan, and entactin (SMIN6E). The num-Glucose-dependent secretion is an important feature ber of cells per spheroid was counted by WST-1 assay of MIN6 cells as a potential source of cell transplant for (Takara Shuzo). The medium was replaced every 7 days. treatment of diabetes mellitus. In order to test whether MIN6 cells and the spheroidal aggregates of MIN6 this character is retained in SMIN6, insulin secretion (SMIN6 and SMIN6E) were encapsulated in agarose miassay was performed. Glucose responsiveness of insucrobeads by the method as described previously (3) . 3) . Reduction on day 28 of the culture. Cells (1.0 × 10 5 ) were cultured of insulin release ratio of SMIN6 in comparison to that in DMEM containing 25 mmol/L glucose, supplemented of MIN6 cells was statistically significant (p < 0.05). with 12% heat-inactivated FBS and penicillin, strepto-Because inclusion of extracellular matrix (ECM) mycin, and amphotericin B (GIBCO BRL; antibioticcomponents in culture medium has been reported to faantimyotic) in a 96-well microplate for 2 days (glucose cilitate insulin secretion from isolated pancreatic islets saturation). Subsequently, cells were washed twice with (1), spheroidal MIN6 cells were generated in the pres-Krebs-Ringer bicarbonate buffer (KRBB) and preincuence of ECM gel (Sigma). Among various concentrabated for 60 min in KRBB containing 3.3 mmol/L glutions of ECM gel tested (25%, 6.25%, 1.56%, 0.39%, cose and 0.5% FBS (glucose starvation). The preincubaand 0.097%), concentrations higher than 0.39% inhibtion medium was discarded and replaced with KRBB ited formation of spheroid aggregates. SMIN6 cells containing 3.3 or 25 mmol/L glucose and 0.5% FBS.
formed in the presence of 0.39% or 0.097% ECM gel The cell suspension was collected after 60 min and cen-(SMIN6E) were morphologically indistinguishable from trifuged. The supernatants were served for insulin mea-SMIN6 cells in the absence of ECM gel and showed surement by ELISA (Mesacup Insulin Test, MBL Co.). similar proliferation profile (data not shown). Insulin The pelleted cells were suspended again in fresh KRBB secretion assay indicated favorable glucose-dependent containing 3.3 mmol/L glucose and 0.5% FBS. The suinsulin secretion, which was comparable to MIN6 cells pernatants were saved for insulin assay after 60 min of in monolayer. SMIN6E formed with 0.39% ECM gel culture.
(27.002 ± 6.14 µU/10 5 /h in 3.3 mmol/L glucose; 139.801 ± 12.56 µU/10 5 /h in 25 mmol/L glucose; n = 4, Fig. 3 ) Statistical Analysis exhibited somewhat better response compared with Insulin release ratio was calculated by dividing insulin SMIN6E cells formed with 0.097% ECM gel (34.531 ± concentration in culture supernatant under 25 mM glucose 9.92 µmU/10 5 /h in 3.3 mmol/L glucose; 136.738 ± 24.58 condition by that under 3.3 mM glucose condition. Data µU/10 5 /h in 25 mmol/L glucose; n = 4). Therefore, ECM were analyzed by a one-way analysis of variance and gel concentration of 0.39% was adopted for later studies. Fisher's PLSD using StatView V software version 4.0.
Insulin secretion was assessed after SMIN6 and Significance criteria in these analyses were p < 0.05. SMIN6E were encapsulated in agarose microbeads (SMIN6-B, SMIN6E-B) (Fig. 1) . SMIN6-B cells possessed the ability for glucose-dependent insulin secretion (24.363 ± 13.4 µU/10 5 /h in 3.3 mmol/L glucose; 71.894 ± 11.3 µU/10 5 /h in 25 mmol/L glucose; n = 4, Fig. 3 ), which is comparable to nonencapsulated SMIN6 cells. On the other hand, SMIN6E-B cells had slightly reduced glucose responsiveness (22.959 ± 4.59 µU/10 5 / h in 3.3 mmol/L glucose; 90.167 ± 9.19 µU/10 5 /h in 25 mmol/L glucose; n = 4) compared with SMIN6E cells, but were still comparable with MIN6-B (17.074 ± 9.31 µU/10 5 /h in 3.3 mmol/L glucose; 85.520 ± 46.3 µmU/ 10 5 /h in 25 mmol/L glucose; n = 4), SMIN6, or SMIN6-B cells in terms of glucose-responsive insulin secretion (Fig. 3) .
DISCUSSION
In the present study, we developed spheroidal MIN6 (SMIN6) cells that retain the ability for glucose-responsive insulin secretion. MIN6 is a unique cell line that has the ability to secrete insulin in response to elevation of extracellular glucose levels unlike other β-cellderived cell lines such as RINm5F, NIT-1, and HIT cells (2). Spheroidal SMIN6 cells have an additional character suitable for transplantation as a treatment of diabetes mellitus: suppressed proliferation for substantial period of time (at least 4 weeks) (Fig. 2) . Furthermore, SMIN6 cells can be encapsulated in agarose microbeads (SMIN6-B) without losing their ability for glucose-dependent insulin secretion (Fig. 3) . The three features of SMIN6-B 
reason for the constant diameter of SMIN6 cells after
To conclude, this study demonstrated successful results in the regulation of proliferation of MIN6 cells. day 7 is not likely to be necrosis of internal cells but rather cell cycle arrest induced by cell-to-cell contact, Development of spheroid-type MIN6 will contribute to the application of β-cell lines for clinical transplantation because spheroidal aggregates of immortalized cultured cells was reported to induce cell cycle arrest by upregu-and bioartificial organ. In addition, there is a possibility that the method of the development of spheroid-type lating gene expression of cyclin-dependent kinase inhibitor INK4c or p21/CIP/WAF (5) . Another study demon-MIN6 may be applied to clinical transplantation of other cell lines, such as hepatocyte or dopamine-secreting strated no sign of oxygen starvation in the internal cells of spheroidal aggregates of a rat fibroblast cell line (4).
cells. SMIN6 or SMIN6-B cells showed significantly re-
